Stockholders approve amended 2024 equity plan with 3.23M share increase and modified evergreen provision

OnKure Therapeutics, Inc.

Shareholders approved one-time increase of 3,231,638 shares (approx. 8% of outstanding) to the 2024 Equity Incentive Plan.
Annual evergreen provision amended: fixed cap of 2,407,100 shares removed; future annual increase set at 5% of outstanding shares beginning FY2027.
Directors R. Michael Carruthers, Valerie M. Jansen, and Edward T. Mathers elected as Class II directors until 2029.
Shareholders ratified KPMG LLP as independent auditor for fiscal year ending Dec. 31, 2026.
Incentive stock option limit under plan set at 8 million shares.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OnKure Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2024 Equity Incentive Plan at the 2026-06-03 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

For Against Abstentions Broker Non-Votes 16,431,575 3,490,523 1,895 5,466,123

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OnKure Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-03 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

R. Michael Carruthers 19,776,757 147,236 5,466,123 Valerie M. Jansen, M.D., Ph.D. 17,796,919 2,127,074 5,466,123 Edward T. Mathers 19,855,396 68,597 5,466,123

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OnKure Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm at the 2026-06-03 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

For Against Abstentions Broker Non-Votes 25,329,425 60,370 321 -

View on SEC.gov

1591 shareholder votes filed in the last 30 days. Browse all shareholder votes →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-257423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.